DOI 10.1080/17582024.2026.2670683
Which medication improves fatigue in patients with multiple sclerosis (MS)?: a systematic review and network meta-analysis.
Аннотация
BACKGROUND
Fatigue is a disabling symptom of multiple sclerosis (MS) with an unknown etiology. Various medications are used to treat MS-related fatigue, but none of the available studies directly compared the head-to-head efficacy of all these medications. So, we designed this meta-analysis to compare the efficacy of these drugs in treating MS-related fatigue.
METHODS
PubMed, Scopus, EMBASE, PsycINFO, and Web of Science were thoroughly searched by two independent researchers on 1 March 2025. Mean difference (SMD) was used as the effect size, and surface under the cumulative ranking curve (SUCRA) was applied to rank interventions.
RESULTS
15 studies were ultimately included in the systematic review. For fatigue severity, none of the medications were superior to placebo. For fatigue impact (MFIS) compared with placebo, Amantadine (MD -12.11, 95% CI -14.28 to -9.94), Dalfampridine (MD -14.05, 95% CI -22.59 to -5.52, and Methylphenidate (MD -5.25, 95% CI -8.44 to -2.06) were associated with statistically significant improvements. In contrast, CBT (MD 1.40, 95% CI -1.99 to 4.80), and Modafinil (MD 0.60, 95% CI -1.26 to 2.46) did not differ significantly from placebo.
CONCLUSIONS
Amantadine, dalfampridine, and methylphenidate were found to be superior to placebo in improving the impact of fatigue on patients' lives.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.